RECURRENT MELANOMA

This early-phase trial tests the safety and best dose of combining two drugs—ziv-aflibercept and pembrolizumab—in people with advanced solid tumors that have spread. Ziv-aflibercept cuts off the tumor's blood supply, while pembrolizumab helps the immune system fight cancer. The s…

This early-phase trial studies the safety and best dose of two drugs, riluzole and sorafenib, given together to adults with advanced solid tumors or melanoma that has spread and is no longer responding to standard treatments. The goal is to find a dose that limits side effects wh…

This study looked at 88 people with advanced melanoma (skin cancer that has spread) that cannot be removed by surgery. Researchers tested two different doses of the drug ipilimumab, either alone or combined with high-dose interferon, to see which approach works better at stopping…

This study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be surgically removed. About 245 participants were randomly assigned to receive ipilimumab alone or with GM-CSF. The main goal was …

This phase III trial tested two different sequences of drugs in 267 people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib), w…

This study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…

This study tests whether combining two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda)—can shrink tumors in people with advanced melanoma that has stopped responding to standard anti-PD1/L1 therapy. About 43 adults with stage III or IV melanoma t…

This study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. About 1,673 patients with high-risk stage III–IV melanoma that was fully removed took part. The main goal was to see w…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests a drug called dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. The goal is to see if it can shrink tumors or slow the disease, and to check for side effects.

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…